July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Comparison of efficacy of intravitreal triamcinolone acetonide versus intravitreal bevacizumab in diabetic patients with macular edema and cataract undergoing phacoemulsification
Author Affiliations & Notes
  • Shikha Bassi
    Cataract, Sankara Nethralaya, Chennai, India
  • Shebin salim
    Cataract, Sankara Nethralaya, Chennai, India
  • Ekta Rishi
    Cataract, Sankara Nethralaya, Chennai, India
  • Footnotes
    Commercial Relationships   Shikha Bassi, None; Shebin salim, None; Ekta Rishi, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4843. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shikha Bassi, Shebin salim, Ekta Rishi; Comparison of efficacy of intravitreal triamcinolone acetonide versus intravitreal bevacizumab in diabetic patients with macular edema and cataract undergoing phacoemulsification. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4843.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the visual outcome in terms of best corrected visual acuity (BCVA) and progression of diabetic maculopathy in terms of central macular thickness (CMT) in patients with diabetic macular edema (DME) and cataract undergoing phacoemulsification with intravitreal bevacizumab (IVB)or intravitreal triamcinolone acetonide(IVTA).

Methods : The study is a retrospective hospital based longitudinal observational comparative study.

Results : Sixty patients (63 eyes) underwent phacoemulsification with IVB injection while 70 patients (75 eyes) had phacoemulsification with IVTA.The mean pre-operative visual acuity in log Mar ±SD in the IVB group was 0.94±0.58 and in IVTA group it was 0.92±0.54, both were comparable(p=0.83). The BCVA improved to 0.52±0.47 in the bevacizumab group at 3 weeks follow up and 0.51±0.45 at 3 months follow up, both were statistically significant compared to the preoperative visual acuity (p=0.00).In the IVTA group the mean pre-operative BCVA in logmar±SD was 0.92±0.54 and the mean BCVA improved to 0.40±0.26 at 3 weeks follow up and 0.48±0.32 at 3 months follow up,both were statistically significant compared to preoperative level(p=0.00).The mean pre-operative central macular thickness in the IVB group was 396.41±170.20, at 3 weeks follow up it was 437.27±217.48 and at 3 months follow up it was 457±206.94.The mean pre-operative central macular thickness in the IVTA group was 467.79±179.92 ,at 3 weeks follow up it was 382.58±192.30. At 3 months follow up the central macular thickness in the IVTA group was 445.51±222.10.Even though the mean CMT reduced from preoperative level in the IVTA group, the difference was statistically significant only at 3 weeks follow up (p=0.015), at 3 months the decrease in CMT was not statistically significant(p=0.293).

Conclusions : Both IVTA and intravitreal bevacizumab when given along with phacoemulsification in patients with DME improved the vision significantly at 3 weeks and 3 months follow up.The improvement in BCVA was more with IVTA compared to IVB but it was statistically significant only at 3 weeks follow up.The CMT worsened in IVB group and improved in IVTA group, but the improvement in CMT was statistically significant only at 3 weeks follow up.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×